Monoclonal antibodies and Fc fragments for treating solid tumors

Andrea M Eisenbeis, Stefan J GrauDepartment of Neurosurgery, University Hospital of Cologne, Cologne, GermanyAbstract: Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eisenbeis AM, Grau SJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/009d04495ef04c1abc9614686dbac149
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:009d04495ef04c1abc9614686dbac149
record_format	dspace
spelling	oai:doaj.org-article:009d04495ef04c1abc9614686dbac1492021-12-02T08:55:48ZMonoclonal antibodies and Fc fragments for treating solid tumors1177-54751177-5491https://doaj.org/article/009d04495ef04c1abc9614686dbac1492012-01-01T00:00:00Zhttp://www.dovepress.com/monoclonal-antibodies-and-fc-fragments-for-treating-solid-tumors-a8998https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Andrea M Eisenbeis, Stefan J GrauDepartment of Neurosurgery, University Hospital of Cologne, Cologne, GermanyAbstract: Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use of monoclonal antibodies and Fc fragments in various fields in medicine. In this context, a rapidly growing number of these substances have also emerged in the field of oncology. This review will summarize the currently approved monoclonal antibodies used for the treatment of solid tumors with a focus on their clinical application, biological background, and currently ongoing trials.Keywords: targeted therapy, monoclonal antibodies, cancer, biological therapyEisenbeis AMGrau SJDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 13-20 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Eisenbeis AM Grau SJ Monoclonal antibodies and Fc fragments for treating solid tumors
description	Andrea M Eisenbeis, Stefan J GrauDepartment of Neurosurgery, University Hospital of Cologne, Cologne, GermanyAbstract: Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use of monoclonal antibodies and Fc fragments in various fields in medicine. In this context, a rapidly growing number of these substances have also emerged in the field of oncology. This review will summarize the currently approved monoclonal antibodies used for the treatment of solid tumors with a focus on their clinical application, biological background, and currently ongoing trials.Keywords: targeted therapy, monoclonal antibodies, cancer, biological therapy
format	article
author	Eisenbeis AM Grau SJ
author_facet	Eisenbeis AM Grau SJ
author_sort	Eisenbeis AM
title	Monoclonal antibodies and Fc fragments for treating solid tumors
title_short	Monoclonal antibodies and Fc fragments for treating solid tumors
title_full	Monoclonal antibodies and Fc fragments for treating solid tumors
title_fullStr	Monoclonal antibodies and Fc fragments for treating solid tumors
title_full_unstemmed	Monoclonal antibodies and Fc fragments for treating solid tumors
title_sort	monoclonal antibodies and fc fragments for treating solid tumors
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/009d04495ef04c1abc9614686dbac149
work_keys_str_mv	AT eisenbeisam monoclonalantibodiesandfcfragmentsfortreatingsolidtumors AT grausj monoclonalantibodiesandfcfragmentsfortreatingsolidtumors
_version_	1718398281376071680

Monoclonal antibodies and Fc fragments for treating solid tumors

Ejemplares similares